---
title: "Morgan Stanley's investment ratings and target prices for Chinese biopharmaceutical stocks (Table)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277553518.md"
description: "Morgan Stanley released a research report listing the investment ratings and target prices for Chinese biopharmaceutical stocks. The rating for Genscript Biotech is in line with the market, with the target price lowered from 55 yuan to 44 yuan; the rating for Innovent Bio is to overweight, with a target price of 130 yuan; the rating for Visen Pharma-B is to overweight, with the target price lowered from 80 yuan to 50 yuan; the rating for Zai Lab is to overweight, with the target price lowered from 37.5 yuan to 19.5 yuan"
datetime: "2026-03-03T02:30:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277553518.md)
  - [en](https://longbridge.com/en/news/277553518.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277553518.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/277553518.md) | [繁體中文](https://longbridge.com/zh-HK/news/277553518.md)


# Morgan Stanley's investment ratings and target prices for Chinese biopharmaceutical stocks (Table)

Morgan Stanley published a research report, listing the investment ratings and target prices for Chinese biopharmaceutical stocks as follows:

Stock | Investment Rating | Target Price (HKD)

Genscript Biotech Corporation (01952.HK) | Market Perform | 55 HKD -> 44 HKD

INNOVENT BIO (01801.HK) | Overweight | 130 HKD

VISEN PHARMA-B (02561.HK) | Overweight | 80 HKD -> 50 HKD

ZAI LAB (09688.HK) | Overweight | 37.5 HKD -> 19.5 HKD

### Related Stocks

- [TEDA BIOMEDICAL (08189.HK)](https://longbridge.com/en/quote/08189.HK.md)
- [VISEN PHARMA-B (02561.HK)](https://longbridge.com/en/quote/02561.HK.md)
- [INNOVENT BIO (01801.HK)](https://longbridge.com/en/quote/01801.HK.md)
- [ZAI LAB (09688.HK)](https://longbridge.com/en/quote/09688.HK.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/en/quote/512290.CN.md)

## Related News & Research

- [Guotai Haitong Remains a Buy on Zai Lab Ltd (1ZLB)](https://longbridge.com/en/news/277338249.md)
- [Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals](https://longbridge.com/en/news/277340041.md)
- [Innovent Biologics' Q4 Revenue Surges 60%](https://longbridge.com/en/news/274820825.md)
- [Sanofi bets on Sino Biopharm’s transplant drug in $1.5bn licensing deal](https://longbridge.com/en/news/277818646.md)
- [Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 billion](https://longbridge.com/en/news/277695972.md)